The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists.

El mejor anticoagulante en fibrilación auricular post TAVI

The purpose of this paper published in JACC Interv was to compare long-term results between classic vitamin K antagonists and novel direct anticoagulant agents in patients with AF who undergo TAVR.

While this is a heterogeneous group of patients, they overall share a higher risk for events, including bleeding. The combination of AF and TAVR magnifies the difficulties of balancing the risk/benefit of different anticoagulation schemes.

The OCEAN Registry prospectively included 2588 patients who underwent TAVR, 403 of whom had AF and were discharged with anticoagulant agents.

The mean age for this population was 84.4 ± 4.7 years, with a CHA2DS2-VASc score of 5.1 ± 1.1. Patients were followed for almost 2 years, and propensity score matching was used to balance baseline characteristics.


Read also: Post MI Betablockers for Good?


The group receiving direct anticoagulant agents showed significantly lower mortality than those receiving vitamin K antagonists (10.3% vs. 23.3%; hazard ratio: 0.391; 95% confidence interval: 0.204 to 0.749; p = 0.005).

Conclusion

Direct anticoagulant agents were linked to lower mortality in patients with atrial fibrillation who underwent TAVR compared with classic vitamin K antagonists.

j-jcin-2020-09-013free

Original Title: Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.

Reference: Hideyuki Kawashima et al. JACC Cardiovasc Interv. 2020 Nov 23;13(22):2587-2597. doi: 10.1016/j.jcin.2020.09.013.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...